News Sentiment

CRNX sentiment intelligence

Crinetics Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 66 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 83.58 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

73/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+97.9% over one week, +142.5% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal

Market Reaction

Price moving ahead of tone

68/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 73/100 classification
One-week reaction 97.9% Price confirming higher
Trend fit Trend inactive 142.5% over four weeks
Fair value 109.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 25
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
Stock Titan 7
simplywall.st 6
Investing.com 2
Motley Fool 2
Investing.com UK 2
MarketBeat 2
Moomoo 2

Event Lens

What the news is about

Classified themes
Market update 23
Deals and strategy 22
Earnings 12
Analyst action 4
Regulatory and legal 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 66
Paul, Weiss Direct company coverage

Crinetics Pharmaceuticals to be Acquired by Vertex Pharmaceuticals in $10 Billion Deal

Paul, Weiss is advising Crinetics Pharmaceuticals, Inc. on its $10 billion all-cash acquisition by Vertex Pharmaceuticals Incorporated. Vertex will acquire Crinetics for $85 per share. The transaction is expected to close in the third quarter of 2026, pending customary closing co

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 01:41
Source
Paul, Weiss
Stock Titan Direct company coverage

Vertex (Nasdaq: VRTX) to acquire Crinetics (CRNX) in $10B cash deal

Vertex Pharmaceuticals announced it will acquire Crinetics Pharmaceuticals for $10 billion in an all-cash deal, paying $85.00 per share. The acquisition will add Crinetics' FDA-approved acromegaly drug PALSONIFY and late-stage asset atumelnant to Vertex's portfolio, with potentia

Tone
Positive 75/100
Event
Deals and strategy
Published
07 Jul 2026 01:10
Source
Stock Titan
Scrip Direct company coverage

Vertex Grows Its Rare Disease Business With $10bn Crinetics Buy

Vertex Pharmaceuticals is expanding its rare disease portfolio by acquiring Crinetics Pharmaceuticals for $10 billion. This acquisition adds a fifth business group, endocrine diseases, to Vertex's operations, following the recent US and EU approval of Crinetics' drug Palsonify fo

Tone
Positive 72/100
Event
Deals and strategy
Published
07 Jul 2026 00:22
Source
Scrip
PR Newswire Direct company coverage

Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Crinetics Pharmaceuticals (Nasdaq: CRNX) regarding potential breaches of fiduciary duty due to its recently announced transaction with Vertex. Shareholders are set to receive $85.00 per share in cash, totaling approximately $10.0 billion, and Ademi LLP

Tone
Negative 40/100
Event
Balance sheet
Published
07 Jul 2026 00:10
Source
PR Newswire
Market source Direct company coverage

CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition

Shares of Crinetics Pharmaceuticals (CRNX) surged nearly 100% in after-hours trading after Vertex Pharmaceuticals (VRTX) announced its intention to acquire the company for approximately $10 billion. The acquisition, valuing Crinetics at $85 per share in cash, aims to strengthen V

Tone
Positive 90/100
Event
Deals and strategy
Published
06 Jul 2026 23:13
Source
Market source
Stock Titan Direct company coverage

If You Invested $1,000 in Crinetics Pharmaceuticals (CRNX)

This article analyzes the historical performance of Crinetics Pharmaceuticals (CRNX) stock, detailing how a $1,000 investment would have grown over 1, 5, and since 2018. It provides a comprehensive overview of the company's focus on endocrine diseases, its FDA-approved drug PALSO

Tone
Positive 74/100
Event
Market update
Published
04 Jul 2026 01:09
Source
Stock Titan
Moomoo Direct company coverage

Crinetics Pharmaceuticals Shares Rise After UBS Initiates Coverage

Crinetics Pharmaceuticals (CRNX) saw its shares increase by over 6% after UBS initiated coverage with a "Buy" rating. The analyst set a price target of $70.00, suggesting significant upside potential for the stock. This positive analyst action reflects growing confidence in the c

Tone
Positive 77/100
Event
Analyst action
Published
03 Jul 2026 12:11
Source
Moomoo
GuruFocus Direct company coverage

Crinetics Pharmaceuticals (CRNX) Receives Buy Rating from UBS with $55 Target GuruFocus News

Crinetics Pharmaceuticals (CRNX) received a Buy rating from UBS with a $55 price target, despite a recent stock decline, due to anticipated success of its drug atumelnant and its flagship product, Palsonify. However, the company faces challenges including a low GF Score of 47/100

Tone
Positive 67/100
Event
Analyst action
Published
03 Jul 2026 01:39
Source
GuruFocus
Investing.com Direct company coverage

UBS initiates Crinetics stock with buy rating, $55 price target

UBS has initiated coverage on Crinetics Pharmaceuticals Inc. (CRNX) with a buy rating and a price target of $55, citing potential upside from its current price of $38.68. The firm projects risk-adjusted peak sales of $2.0 billion for the company’s Phase 3 atumelnant in Congenital

Tone
Positive 71/100
Event
Analyst action
Published
02 Jul 2026 23:41
Source
Investing.com
Investing.com Canada Direct company coverage

Form 144 Crinetics Pharmaceuticals For: 2 July By Investing.com

This article from Investing.com reports on a Form 144 filing for Crinetics Pharmaceuticals (CRNX) on July 2. The filing is a regulatory notice indicating the intent to sell restricted securities. The article includes the stock symbol and notes a 9.18% increase for CRNX.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
02 Jul 2026 21:10
Source
Investing.com Canada